220 related articles for article (PubMed ID: 35151276)
1. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
4. Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
[TBL] [Abstract][Full Text] [Related]
5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
6. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.
Sieuwerts AM; Ansems M; Look MP; Span PN; de Weerd V; van Galen A; Foekens JA; Adema GJ; Martens JW
Breast Cancer Res; 2010; 12(6):R103. PubMed ID: 21122099
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
[TBL] [Abstract][Full Text] [Related]
9. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
10. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Lei JT; Shao J; Zhang J; Iglesia M; Chan DW; Cao J; Anurag M; Singh P; He X; Kosaka Y; Matsunuma R; Crowder R; Hoog J; Phommaly C; Goncalves R; Ramalho S; Peres RMR; Punturi N; Schmidt C; Bartram A; Jou E; Devarakonda V; Holloway KR; Lai WV; Hampton O; Rogers A; Tobias E; Parikh PA; Davies SR; Li S; Ma CX; Suman VJ; Hunt KK; Watson MA; Hoadley KA; Thompson EA; Chen X; Kavuri SM; Creighton CJ; Maher CA; Perou CM; Haricharan S; Ellis MJ
Cell Rep; 2018 Aug; 24(6):1434-1444.e7. PubMed ID: 30089255
[TBL] [Abstract][Full Text] [Related]
11. ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
Karsono R; Haryono SJ; Karsono B; Harahap WA; Pratiwi Y; Aryandono T
BMC Cancer; 2021 Dec; 21(1):1348. PubMed ID: 34930150
[TBL] [Abstract][Full Text] [Related]
12. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
Houtsma D; de Groot S; Baak-Pablo R; Kranenbarg EM; Seynaeve CM; van de Velde CJH; Böhringer S; Kroep JR; Guchelaar H-; Gelderblom H
Sci Rep; 2021 Feb; 11(1):3249. PubMed ID: 33547330
[TBL] [Abstract][Full Text] [Related]
13. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
14. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.
Ejlertsen B; Aldridge J; Nielsen KV; Regan MM; Henriksen KL; Lykkesfeldt AE; Müller S; Gelber RD; Price KN; Rasmussen BB; Viale G; Mouridsen H;
Ann Oncol; 2012 May; 23(5):1138-1144. PubMed ID: 21986093
[TBL] [Abstract][Full Text] [Related]
16. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
Lundgren C; Tutzauer J; Church SE; Stål O; Ekholm M; Forsare C; Nordenskjöld B; Fernö M; Bendahl PO; Rydén L
Breast Cancer Res; 2023 Sep; 25(1):110. PubMed ID: 37773134
[TBL] [Abstract][Full Text] [Related]
18. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
[TBL] [Abstract][Full Text] [Related]
19. The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.
Atmaca A; Al-Batran SE; Wirtz RM; Werner D; Zirlik S; Wiest G; Eschbach C; Claas S; Hartmann A; Ficker JH; Jäger E; Brueckl WM
Int J Cancer; 2014 May; 134(10):2314-21. PubMed ID: 24174373
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]